Arbutus Biopharma Corp Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2021-12-10: Form 8-K; Exhibit 10.1; Description Third Amendment to Cross License Agreement, dated December 9, 2021, by and between Genevant Sciences GmbH and Arbutus Biopharma Corporation.
- 2021-06-01: Form 8-K; Exhibit 10.1; Description Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended.
- 2021-03-04: Form 8-K; Exhibit 10.1; Description Amendment No. 3 to the Open Market Sale AgreementSM, dated March 4, 2021, by and between Arbutus Biopharma Corporation and Jefferies LLC..
| Filed | Form | Exhibit | Description |
|---|
| 2021-12-10 | 8-K | 10.1 | Third Amendment to Cross License Agreement, dated December 9, 2021, by and between Genevant Sciences GmbH and Arbutus Biopharma Corporation |
|---|
| 2021-06-01 | 8-K | 10.1 | Arbutus Biopharma Corporation 2016 Omnibus Share and Incentive Plan, as supplemented and amended |
|---|
| 2021-03-04 | 8-K | 10.1 | Amendment No. 3 to the Open Market Sale AgreementSM, dated March 4, 2021, by and between Arbutus Biopharma Corporation and Jefferies LLC. |
|---|